Elsevier

Advanced Drug Delivery Reviews

Volume 60, Issue 11, 17 August 2008, Pages 1252-1265
Advanced Drug Delivery Reviews

Magnetic nanoparticles in MR imaging and drug delivery

https://doi.org/10.1016/j.addr.2008.03.018Get rights and content

Abstract

Magnetic nanoparticles (MNPs) possess unique magnetic properties and the ability to function at the cellular and molecular level of biological interactions making them an attractive platform as contrast agents for magnetic resonance imaging (MRI) and as carriers for drug delivery. Recent advances in nanotechnology have improved the ability to specifically tailor the features and properties of MNPs for these biomedical applications. To better address specific clinical needs, MNPs with higher magnetic moments, non-fouling surfaces, and increased functionalities are now being developed for applications in the detection, diagnosis, and treatment of malignant tumors, cardiovascular disease, and neurological disease. Through the incorporation of highly specific targeting agents and other functional ligands, such as fluorophores and permeation enhancers, the applicability and efficacy of these MNPs have greatly increased. This review provides a background on applications of MNPs as MR imaging contrast agents and as carriers for drug delivery and an overview of the recent developments in this area of research.

Introduction

Magnetic nanoparticles (MNPs) are a major class of nanoscale materials with the potential to revolutionize current clinical diagnostic and therapeutic techniques. Due to their unique physical properties and ability to function at the cellular and molecular level of biological interactions, MNPs are being actively investigated as the next generation of magnetic resonance imaging (MRI) contrast agents [1] and as carriers for targeted drug delivery [2], [3]. Although early research in the field can be dated back several decades, the recent surge of interest in nanotechnology has significantly expanded the breadth and depth of MNP research. With a wide range of applications in the detection, diagnosis, and treatment of illnesses, such as cancer [4], cardiovascular disease [5], and neurological disease [6], MNPs may soon play a significant role in meeting the healthcare needs of tomorrow.

Numerous forms of MNP with various chemical compositions have been proposed and evaluated for biomedical applications to exploit nanoscale magnetic phenomena, such as enhanced magnetic moments and superparamagnetism. Like other nanomaterial-based systems, advances in nanotechnology now allow for precise engineering of the critical features of these fine particles. Composition, size, morphology and surface chemistry can now be tailored by various processes to not only improve magnetic properties but also affect the behavior of nanoparticles in vivo [7], [8]. In its simplest form, a biomedical MNP platform is comprised of an inorganic nanoparticle core and a biocompatible surface coating that provides stabilization under physiological conditions. Additionally, the application of suitable surface chemistry allows for the integration of functional ligands [9]. This modular design enables MNPs to perform multiple functions simultaneously, such as in multimodal imaging [10], drug delivery and real-time monitoring, as well as combined therapeutic approaches.

The ability of MNPs to enhance proton relaxation of specific tissues and serve as MR imaging contrast agents is one of the most promising applications of nanomedicine. MNPs in the form of superparamagnetic iron oxides (SPIO) have been actively investigated as MR imaging contrast agents for over two decades [11]. With applications, such as bowel contrast agents (i.e., Lumiren® and Gastromark®) and liver/spleen imaging (i.e., Endorem® and Feridex IV®) [12], [13], already on the market, SPIOs have led the way for MNPs into the clinic. Several forms of ultrasmall superparamagnetic iron oxides (USPIO) have undergone clinical trials with one of the most notable being Combidex® which is in late stage clinical trials for use in the detection of lymph node metastases [14].

As therapeutic tools, MNPs have been evaluated extensively for targeted delivery of pharmaceuticals through magnetic drug targeting (MDT) [15], [16] and by active targeting through the attachment of high affinity ligands [17], [18], [19]. In the spirit of Ehrlich's “Magic Bullet” [20], MNPs have the potential to overcome limitations associated with systemic distribution of conventional chemotherapies. With the ability to utilize magnetic attraction and/or specific targeting of disease biomarkers, MNPs offer an attractive means of remotely directing therapeutic agents specifically to a disease site, while simultaneously reducing dosage and the deleterious side effects associated with non-specific uptake of cytotoxic drugs by healthy tissue. Also referred to as magnetic targeted carriers (MTC), colloidal iron oxide particles in early clinical trials have demonstrated some degree of success with the technique and shown satisfactory toleration by patients [21], [22]. Although not yet capable of reaching levels of safety and efficacy for regulatory approval, pre-clinical studies indicated that some of the shortcomings of MDT technology, such as poor penetration depth and diffusion of the released drug from the disease site, can be overcome by improvements in MTC design [23], [24]. Furthermore, the use of MNP as carriers in multifunctional nanoplatforms as a means of real-time monitoring of drug delivery is an area of intense interest [25], [26].

A significant challenge associated with the application of these MNP systems is their behavior in vivo. The efficacy of many of these systems is often compromised due to recognition and clearance by the reticuloendothelial system (RES) prior to reaching target tissue, as well as by an inability of to overcome biological barriers, such as the vascular endothelium or the blood brain barrier. The fate of these MNP upon intravenous administration is highly dependent on their size, morphology, charge, and surface chemistry. These physicochemical properties of nanoparticles directly affect their subsequent pharmacokinetics and biodistribution [27]. To increase the effectiveness of MNPs, several techniques, including reducing size and grafting non-fouling polymers, have been employed to improve their “stealthiness” and increase their blood circulation time to maximize the likelihood of reaching targeted tissues [28], [29].

Next-generation MNP-based MR imaging contrast agents and carriers for drug delivery incorporate novel nanocrystalline cores, coating materials, and functional ligands to improve the detection and specific delivery of these nanoparticles. New formulations of MNP cores, such as doped iron oxide nanocrystals, metallic/alloy nanoparticles, and nanocomposites, offer high magnetic moments increasing their signal-to-background ratios under MRI. Concurrently, the use of new surface coatings, such as stable gold or silica shell structures, allows for the application of otherwise toxic core materials, as well as more thorough coating through the formation of self-assembled monolayers (SAMS) on the nanoparticle surface. In addition, recent studies and reviews indicate an increasing role of cellular mechanics in diseases such as malaria [30], [31] and cancer metastasis [32], [33], [34]. As such, there is potential for next-generation platforms to incorporate surface qualities that would enable probing and/or monitoring of local physical mechanistic changes at a length scale that would greatly assist in improving disease detection, monitoring, and treatment.

Although many are still early in pre-clinical evaluation, with work still necessary to address the metabolism and potential long-term toxicity of these MNPs, efforts such as that of the National Cancer Institute (NCI) Nanotechnology Characterization Laboratory (NCL) are accelerating the evaluation of these new nanomaterials allowing for even quicker development in this already rapidly growing field. This review examines some of the recent developments in MNP technology and provides a brief background of their applications as MR imaging contrast agents and as carriers for drug delivery.

Section snippets

Magnetic properties

The penetration of magnetic fields through human tissue and the ability to remotely detect or manipulate magnetic materials have been investigated for use in medicine for centuries [35]. One of the more recent and significant applications of these properties has been in MRI as a non-invasive imaging modality capable of providing high resolution anatomical images. However, the potential of current clinical medical imaging can be greatly expanded through the use of MNPs to improve differentiation

Polymeric coatings

Surface coatings are an integral component of all MNP platforms for biomedical applications. Although not attracted magnetically, due to their superparamagnetic properties, nanoparticles still have a significant tendency to agglomerate as a result of their high surface energy. Colloidal electrostatic stabilization arising from repulsion of surface charges on the nanoparticles is typically not adequate to prevent aggregation in biological solutions due to the presence of salts or other

Blood half-life

The need to extend nanoparticles' blood circulation time to allow for their accumulation in target tissues has long been recognized as one of the primary challenges in the development of MNPs [29]. The ability to evade uptake by the RES is critical to achieving a long blood half-life. Like other colloidal carriers, the physicochemical properties of these MNP platforms, such as size, morphology, charge, and surface chemistry, dictate their fate in vivo.

The overall size of MNPs must be

Magnetic properties and MRI contrast enhancement

MR imaging is one of the most powerful non-invasive imaging modalities utilized in clinical medicine today [160], [161]. MR imaging is based on the property that hydrogen protons will align and process around an applied magnetic field, B0. Upon application of a transverse radiofrequency (rf) pulse, these protons are perturbed from B0. The subsequent process through which these protons return to their original state is referred to as the relaxation phenomenon. Two independent processes,

Magnetic drug targeting (MDT)

The primary shortcoming of most chemotherapeutic agents is their relative non-specificity and thus potential side effects to healthy tissues. To overcome this problem, MDT utilizes the attraction of MNP carriers to an external magnetic field to increase site-specific delivery of therapeutic agents [2], [3]. In general, this process involves the attachment of a cytotoxic drug to a biocompatible MNP carrier (a.k.a. magnetic targeted carrier or MTC), intravenous injection of these MTCs in the form

Conclusions

The development of MNPs has been greatly accelerated in the past decade by advances in nanotechnology, molecular cell biology, and small-animal imaging instrumentation. MNPs of various formulations have been developed to diagnose and treat diseases for which conventional therapy has shown limited efficacy. In particular, the use of MNPs as MRI contrast agents and drug carriers has drawn enormous attention, as it holds great potential of providing new opportunities for early cancer detection and

Acknowledgements

This work was supported in part by NIH/NCI Nanoplatform grant (R01CA119408), NIH/NCI grant (R01CA134213), and NIH/NIBIB grant (R01EB006043).

References (202)

  • S. Suresh

    Biomechanics and biophysics of cancer cells

    Acta Biomaterialia

    (2007)
  • G.P. Gupta et al.

    Cancer metastasis: building a framework

    Cell

    (2006)
  • X.M. Lin et al.

    Synthesis, assembly and physical properties of magnetic nanoparticles

    Journal of Magnetism and Magnetic Materials

    (2006)
  • R.S. Molday et al.

    Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells

    Journal of Immunological Methods

    (1982)
  • S. Rana et al.

    On the suitability of nanocrystalline ferrites as a magnetic carrier for drug delivery: functionalization, conjugation and drug release kinetics

    Acta Biomaterialia

    (2007)
  • D. Portet et al.

    Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents

    Journal of Colloid and Interface Science

    (2001)
  • N. Fauconnier et al.

    Thiolation of maghemite nanoparticles by dimercaptosuccinic acid

    Journal of Colloid and Interface Science

    (1997)
  • S. Mornet et al.

    Magnetic nanoparticle design for medical applications

    Progress in Solid State Chemistry

    (2006)
  • M.D. Butterworth et al.

    Preparation of ultrafine silica- and PEG-coated magnetite particles

    Colloids and Surfaces. A, Physicochemical and Engineering Aspects

    (2001)
  • J. Lee et al.

    Preparation of ultrafine Fe3O4 particles by precipitation in the presence of PVA at high pH

    Journal of Colloid and Interface Science

    (1996)
  • S. Lecommandoux et al.

    Smart hybrid magnetic self-assembled micelles and hollow capsules

    Progress in Solid State Chemistry

    (2006)
  • W. Stober et al.

    Controlled growth of monodisperse silica spheres in micron size range

    Journal of Colloid and Interface Science

    (1968)
  • Q.A. Pankhurst et al.

    Applications of magnetic nanoparticles in biomedicine

    Journal of Physics. D, Applied Physics

    (2003)
  • J. Dobson

    Magnetic nanoparticles for drug delivery

    Drug Development Research

    (2006)
  • M. Ferrari

    Cancer nanotechnology: opportunities and challenges

    Nature Reviews. Cancer

    (2005)
  • S.A. Wickline et al.

    Molecular imaging and therapy of atherosclerosis with targeted nanoparticles

    Journal of Magnetic Resonance Imaging

    (2007)
  • C. Corot et al.

    Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging

    Investigative Radiology

    (2004)
  • P. Tartaj et al.

    The preparation of magnetic nanoparticles for applications in biomedicine

    Journal of Physics. D, Applied Physics

    (2003)
  • S.E. McNeil

    Nanotechnology for the biologist

    Journal of Leukocyte Biology

    (2005)
  • L. Frullano et al.

    Multimodal MRI contrast agents

    Journal of Biological Inorganic Chemistry

    (2007)
  • Y.X. Wang et al.

    Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

    European Radiology

    (2001)
  • B. Bonnemain

    Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications — a review

    Journal of Drug Targeting

    (1998)
  • M.G. Harisinghani et al.

    Noninvasive detection of clinically occult lymph-node metastases in prostate cancer

    New England Journal of Medicine

    (2003)
  • A. Senyei et al.

    Magnetic guidance of drug-carrying microspheres

    Journal Of Applied Physics

    (1978)
  • O. Veiseh et al.

    Optical and MRI multifunctional nanoprobe for targeting gliomas

    Nano Letters

    (2005)
  • A.S. Lubbe et al.

    Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors

    Cancer Research

    (1996)
  • J.M. Gallo et al.

    Preclinical experiences with magnetic drug targeting: tolerance and efficacy and clinical experiences with magnetic drug targeting: a phase I study with 4¢-epidoxorubicin in 14 patients with advanced solid tumors

    Cancer Research

    (1997)
  • N. Kohler et al.

    Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells

    Langmuir

    (2005)
  • N. Kohler et al.

    Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery

    Small

    (2006)
  • C. Chouly et al.

    Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution

    Journal of Microencapsulation

    (1996)
  • S.M. Moghimi et al.

    Long-circulating and target-specific nanoparticles: theory to practice

    Pharmacological Reviews

    (2001)
  • M. Puig-de-Morales-Marinkovic et al.

    Viscoelasticity of the human red blood cell

    American Journal of Physiology. Cell Physiology

    (2007)
  • E. Sahai

    Illuminating the metastatic process

    Nature Reviews. Cancer

    (2007)
  • P.S. Steeg

    Tumor metastasis: mechanistic insights and clinical challenges

    Natural Medicines

    (2006)
  • M.R. Mourino

    From Thales to Lauterbur, or from the lodestone to MR imaging: magnetism and medicine

    Radiology

    (1991)
  • A. Morrish

    The Physical Principles of Magnetism

    (2001)
  • A.H. Lu et al.

    Magnetic nanoparticles: synthesis, protection, functionalization, and application

    Angewandte Chemie. International Edition

    (2007)
  • R. Weissleder et al.

    Superparamagnetic iron oxide: pharmacokinetics and toxicity

    AJR. American Journal of Roentgenology

    (1989)
  • M.A. Willard et al.

    Chemically prepared magnetic nanoparticles

    International Materials Reviews

    (2004)
  • T. Shen et al.

    Monocrystalline iron oxide nanocompounds (MION): physicochemical properties

    Magnetic Resonance in Medicine

    (1993)
  • Cited by (2278)

    View all citing articles on Scopus

    This review is part of the Advanced Drug Delivery Reviews theme issue on “Inorganic Nanoparticles in Drug Delivery”.

    View full text